Zymeworks Inc.: Zymeworks Outlines Strategic Priorities and Outlook for 2026

Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) ...
Taiwan News

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Esperion will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025, at 2:15 p.m. PT (5:15 p.m. ET).

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating ...

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on ...

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, provided a business update including ...

Empowering IT Leaders: New CIO Seminar Anchored on Digital Strategy Platform

The CIO Seminar goes far beyond traditional IT training. It positions the CIO as a central architect of corporate strategy, innovation, and value creation. A key differentiator of the program is its ...